Wang Fang, Yang Zhuang, Liu Yibin, Ma Liang, Wu Yuzhe, He Lin, Shao Mingfeng, Yu Kun, Wu Wenshuang, Pu Yuzhi, Nie Chunlai, Chen Lijuan
State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China; Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, 29 Wangjiang Road, Chengdu 610064, PR China.
Bioorg Med Chem. 2015 Jul 1;23(13):3337-50. doi: 10.1016/j.bmc.2015.04.055. Epub 2015 Apr 24.
By switching position of the N and S atom in the thiazole ring which were similar to the previously reported agent 5-(4-ethoxyphenyl)-4-(3',4',5'-trimethoxyphenyl)thiazol-2-amine, a series of 4,5-diarylthiazole derivatives were synthesized using Friedel-Crafts reaction based on chemical modification of Combrestatatin A-4 (CA-4). Their antiproliferative activities were evaluated and identified as new microtubule destabilizing agents. Structure-activity relationship study indicated that compound 8a with 3,4,5-trimethoxyphenyl group at the C-4 position and 4-ethoxyphenyl group at the C-5 position of 2-amino substituted thiazole was of the most potent inhibitory activity in this series. 8a was found to exhibit the IC50 values of 8.4-26.4nM in five human cancer cell lines, with comparable inhibition effects to CA-4. Moreover, 8a showed potency as a tubulin polymerization inhibitor, with colchicine site binding ability and comparable extent of inhibition against the growth of P-glycoprotein over-expressing multidrug resistant cell lines. Mechanism studies revealed that 8a could block the progression of cell cycle in the G2/M phase and result in cellular apoptosis in cancer cells. As a new tubulin destabilizing agent, 8a was also found high antivascular activity as it concentration-dependently reduced the cell migration and disrupted capillary like tube formation of HUVEC cells. Furthermore, 8a significantly suppressed the tumor growth in HCT116 and SK-OV-3 xenograft models with tumor growth inhibitory rate of 55.12% and 72.7%, respectively. Our studies highlighted that 8a was a promising microtubule targeting antitumor agent.
通过改变噻唑环中氮原子和硫原子的位置(这与之前报道的药物5-(4-乙氧基苯基)-4-(3',4',5'-三甲氧基苯基)噻唑-2-胺类似),基于康普他汀A-4(CA-4)的化学修饰,利用傅克反应合成了一系列4,5-二芳基噻唑衍生物。对它们的抗增殖活性进行了评估,并确定它们为新型微管去稳定剂。构效关系研究表明,在2-氨基取代噻唑的C-4位带有3,4,5-三甲氧基苯基基团且在C-5位带有4-乙氧基苯基基团的化合物8a在该系列中具有最强的抑制活性。发现8a在五种人类癌细胞系中的IC50值为8.4 - 26.4nM,其抑制效果与CA-4相当。此外,8a表现出作为微管蛋白聚合抑制剂的活性,具有秋水仙碱位点结合能力,并且对过表达P-糖蛋白的多药耐药细胞系的生长具有相当程度的抑制作用。机制研究表明,8a可阻断细胞周期在G2/M期的进程,并导致癌细胞发生细胞凋亡。作为一种新型的微管去稳定剂,8a还具有高抗血管活性,因为它能浓度依赖性地降低细胞迁移并破坏人脐静脉内皮细胞(HUVEC)的毛细血管样管形成。此外,8a在HCT116和SK-OV-3异种移植模型中显著抑制肿瘤生长,肿瘤生长抑制率分别为55.12%和72.7%。我们的研究突出表明8a是一种有前景的微管靶向抗肿瘤药物。